Edition:
United States

Agilent Technologies Inc (A)

A on New York Consolidated

64.73USD
25 Sep 2017
Change (% chg)

$-1.05 (-1.60%)
Prev Close
$65.78
Open
$65.80
Day's High
$65.90
Day's Low
$64.44
Volume
1,727,461
Avg. Vol
1,887,396
52-wk High
$66.45
52-wk Low
$42.92

Latest Key Developments (Source: Significant Developments)

Agilent Technologies receives expanded FDA approval for Dako PD-L1 IHC 22C3 pharmDx
Friday, 22 Sep 2017 04:27pm EDT 

Sept 22 (Reuters) - Agilent Technologies Inc :Agilent Technologies receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 pharmDx companion diagnostic in gastric or gastroesophageal junction (GEJ) cancer.  Full Article

Agilent announces expanded use of cancer diagnostic in U.S.
Tuesday, 19 Sep 2017 09:00am EDT 

Sept 19 (Reuters) - Agilent Technologies Inc ::Says ‍FDA approved cancer diagnostic for use in cases of UC and of Squamous Cell Carcinoma of head & neck​.  Full Article

AGILENT OBTAINS U.S. FDA APPROVAL FOR GENETISURE DX POSTNATAL ASSAY
Wednesday, 13 Sep 2017 11:00am EDT 

Sept 13 (Reuters) - Agilent Technologies Inc ::AGILENT OBTAINS U.S. FDA APPROVAL FOR GENETISURE DX POSTNATAL ASSAY.AGILENT TECHNOLOGIES INC - ‍ASSAY IS INTENDED FOR USE ON AGILENT SURESCAN DX MICROARRAY SCANNER SYSTEM​.  Full Article

Agilent Technologies reports Q3 non-GAAP earnings per share of $0.59
Tuesday, 15 Aug 2017 04:05pm EDT 

Aug 15 (Reuters) - Agilent Technologies Inc :Agilent Technologies reports third-quarter fiscal year 2017 financial results.Sees Q4 2017 non-GAAP earnings per share $0.60 to $0.62.Sees FY 2017 non-GAAP earnings per share $2.29 to $2.31.Q3 GAAP earnings per share $0.54.Sees Q4 2017 revenue $1.15 billion to $1.17 billion.Sees FY 2017 revenue $4.435 billion to $4.455 billion.Q3 earnings per share view $0.52 -- Thomson Reuters I/B/E/S.Q3 non-GAAP earnings per share $0.59.Agilent Technologies Inc - ‍raising fiscal year 2017 free cash flow guidance by $40 million to $665 million​.Agilent Technologies Inc - qtrly ‍revenue of $1.11 billion, representing growth of 7 percent​.FY 2017 earnings per share view $2.23, revenue view $4.40 billion -- Thomson Reuters I/B/E/S.Q3 revenue view $1.09 billion -- Thomson Reuters I/B/E/S.  Full Article

Agilent acquires Next Generation Sequencing IP portfolio
Monday, 24 Jul 2017 04:30pm EDT 

July 24 (Reuters) - Agilent Technologies Inc :Agilent acquires powerful Next Generation Sequencing IP portfolio.Agilent Technologies Inc - ‍financial terms of purchase were not disclosed​.Agilent Technologies Inc - ‍acquired Population Genetics IP includes patents related to both molecular and sample barcoding​.  Full Article

Agilent Technologies says on July 14 entered into amendment no.1 to credit agreement with lenders and agent - SEC filing
Monday, 17 Jul 2017 04:28pm EDT 

July 17 (Reuters) - Agilent Technologies Inc :Agilent Technologies Inc - on July 14, 2017, company, lenders and agent entered into amendment number 1 to credit agreement - SEC filing.Agilent Technologies Inc - amendment further increased commitments under facility by an additional $300 million - SEC filing.Agilent Technologies Inc - aggregate commitments under facility now total $1.0 billion.  Full Article

Agilent Technologies acquires Raman Spectroscopy Innovator
Friday, 7 Jul 2017 08:30am EDT 

July 7 (Reuters) - Agilent Technologies Inc :Agilent Technologies acquires Raman Spectroscopy innovator, Cobalt Light Systems.Agilent Technologies Inc - Agilent is acquiring Cobalt for £40 million in cash.Says Cobalt's CEO will remain with Agilent as director of Raman Spectroscopy.  Full Article

Agilent Technologies, Agendia to develop RNA-SEQ kit version of Agendia's mammaprint, blueprint tests
Friday, 2 Jun 2017 11:00am EDT 

June 2 (Reuters) - Agilent Technologies Inc ::Co, Agendia Inc to expand relationship to develop RNA-SEQ kit version of Agendia's currently marketed mammaprint, blueprint tests.Agreement accelerates development of tests to assess risk of disease recurrence in women with early-stage breast cancer.Initial phase of RNA-SEQ kit development is expected to be completed in 2017, providing early access to limited markets in Europe.  Full Article

Agilent Technologies reports Q2 EPS $0.48
Monday, 22 May 2017 04:05pm EDT 

May 22 (Reuters) - Agilent Technologies Inc :Reports second-quarter fiscal year 2017 financial results.Sees Q3 non-GAAP earnings per share $0.49 to $0.51.Sees FY 2017 non-Gaap earnings per share $2.15 to $2.21.Q2 GAAP earnings per share $0.50.Sees Q3 2017 revenue $1.06 billion to $1.08 billion.Sees FY 2017 revenue $4.36 billion to $4.38 billion.Q2 earnings per share view $0.48 -- Thomson Reuters I/B/E/S.Q2 non-GAAP earnings per share $0.58.Q2 earnings per share view $0.48 -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $2.16 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.53 -- Thomson Reuters I/B/E/S.Qtrly revenue $1,102 million versus $1,019 million.Q2 revenue view $1.05 billion -- Thomson Reuters I/B/E/S.Q3 revenue view $1.08 billion -- Thomson Reuters I/B/E/S.  Full Article

Agilent Technologies' CEO Michael Mcmullen 2016 total compensation was $8.9 mln vs. $7.2 mln in 2015 - SEC Filing
Thursday, 2 Feb 2017 04:35pm EST 

Agilent Technologies Inc :Agilent Technologies Inc - CEO Michael R. Mcmullen 2016 total compensation was $8.9 million versus $7.2 million in 2015 - SEC Filing.  Full Article

BRIEF-Agilent Technologies receives expanded FDA approval for Dako PD-L1 IHC 22C3 pharmDx

* Agilent Technologies receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 pharmDx companion diagnostic in gastric or gastroesophageal junction (GEJ) cancer Source text for Eikon: Further company coverage: